Mologen Ag

Mologen Forschungs Entwicklungs Und Vertriebs Gmbh

Soft Gene Gmbh

Burghardt Wittig

Matthias Schroff

Manuel Schmidt

Claas Junghans

Kerstin Kapp

Laura Fuertes-López

Marcos Timón-Jiménez

Tomislav Dobric

Heribert Bohlen

Christiane Juhls

Christiane Kleuss

Janine Loehr

Bernadette Brzezicha

Florian Sack

Sven König Merediz

Janine Löhr

The present invention relates to a covalently closed DNA construct, a pharmaceutical composition and a vaccine and their use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising a specific DNA sequence.

Covalently closed non-coding immunomodulatory DNA construct

The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.

Predictive biomarker for cancer therapy

The invention relates to a multimeric non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a preparation process therefore and a vaccine which comprises the multimeric non-coding nucleic acid molecule.

Multimer for immunostimulation

A vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of defined tumor diseases, and a method for the making of such vaccine is disclosed. The tumor cells were previously transfected ex vivo with expression constructs encoding cytokines and co-stimulatory factors.

Allogeneic tumor therapeutic agent, a vaccine using allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such a vaccine, and transfected human tumor cells for use as a vaccine

The invention relates to the use of immune modulators on the basis of DNA in the form of covalently closed nucleic acid molecules comprising immune stimulatory sequence motifs, for the production of a pharmaceutical for the therapeutic treatment of tumor diseases in combination with chemotherapeutic drugs.

Immune modulating oligonucleotides in connection with chemotherapeutic measures

The invention relates to using a combination of DNA-expression constructs for producing a drug for immunization againstinfections and a corresponding vaccine. The DNA-expression construct is also disclosed. According to said invention the immunogene P36 LACK is used in combination with athiol-specific antioxidant protein gene (TSA),kinetoplastid membrane protein 11 (KMP-11) and with aGP63 antigen for producing an immune response. Plasmides, preferably minimalist immunologically defined gene-expression constructs (MIDGE) can be used in the form of the DNA-expression construct. The inventive DNA-expression construct makes it possible to produce a vaccine for treatinginfectious diseases and is used in the form of a component of said vaccine.

[object Object]

Short deoxyribonucleic acid molecules that are partially single-stranded, dumbbell shaped, and covalently closed, which contain one or more unmethylated cytosine guanosine motif (CpG motif) and exhibit immunomodifying effects. Such molecules can be used for immunostimulation applications in humans and vertebrates.

Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals

Use of a combination of DNA expression constructs for the production of a remedy for the immunization against infections with leishmaniasis, as well as a corresponding vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. &#xa7;1.72(b). As stated in 37 C.F.R. &#xa7;1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading 'Abstract of the Disclosure.' The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

Agent for treating leishmania infections

Vaccine on the basis of allogeneic tumor cells for the therapeutic treatment of tumor diseases, and a method for the making of such vaccine, furthermore transfected human tumor cells for their use as a vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. &#xa7;1.72(b). As stated in 37 C.F.R. &#xa7;1.72(b): A brief abstract of the technical disclosure in the specification must commence on a separate sheet, preferably following the claims, under the heading 'Abstract of the Disclosure.' The purpose of the abstract is to enable the Patent and Trademark Office and the public generally to determine quickly from a cursory inspection the nature and gist of the technical disclosure. The abstract shall not be used for interpreting the scope of the claims. Therefore, any statements made relating to the abstract are not intended to limit the claims in any manner and should not be interpreted as limiting the claims in any manner.

The invention concerns an expressible nucleic acid construct, which contains only the sequence information necessary for expressing a gene for RNA or protein synthesis. Expression constructs of this type can be used in gene therapy and genetic vaccination and avoid many of the risks associated with constructs today. The invention further concerns the possibility of improving the conveying of the construct into cells or tissue by covalent linkage of the construct, for example to particles of peptides.

Design principle for the construction of expression constructs for gene therapy

Short deoxyribonucleic acid molecules that are partially single-stranded, dumbbell-shaped, and covalently closed, which contain one or more unmethylated cytosine guanosine motif (CpG motif) and exhibit immunomodifying effects. Such molecules can be used for immunostimulation applications in humans or vertebrates.

Covalently closed nucleic acid molecules for immunostimulation

The invention concerns an expressible nucleic acid construct, which contains only the sequence information necessary for expressing a gene for RNA or protein synthesis. Expression constructs of this type can be used in gene therapy and genetic vaccination and avoid many of the risks associated with constructs today. The invention further concerns the possibility of improving the conveying of the construct into cells or tissue by covalent linkage of the construct, for example to particles or peptides.

Design principle for construction of expression constructs for gene therapy

A process to obtain linear double-stranded covalently closed DNA &ldquo;dumbbell&rdquo; constructs from plasmids by restriction digest, subsequent ligation with hairpin oligodesoxyribonucleotides, optionally in the presence of restriction enzyme, and a final digestion with endo- and exonucleolytic enzymes that degrade all contaminating polymeric DNA molecules but the desired construct. The invention also provides a process to obtain said dumbbell constructs employing endonuclease class II enzymes. Furthermore, the invention provides a process to obtain linear, covalently closed DNA molecules, such as plasmids, free from contamination by genomic DNA, by submitting the DNA preparation to a facultative endonucleolytic degradation step and an obligatory exonucleolytic degradation step.

Growing community of inventors

Berlin, Germany

Burghardt Wittig